Rosen Discusses FDA's Plan to Conduct More Extensive Studies of Generic Blood Pressure Medications
May 6, 2014
Bloomberg
Partner David Rosen was quoted in a Bloomberg article published on May 6, 2014, titled “Blood-Pressure Drug With Thousands of Complaints Draws FDA Test.” The article discussed the U.S. Food and Drug Administration’s plan to conduct more extensive studies of generic blood pressure medications after receiving numerous complaints of ineffectiveness and troublesome side effects. Rosen was quoted saying, “It’s an important issue and we want to make sure these products perform in the way they’re supposed to perform.”
People
Related News
April 3, 2026
In the News
David Rosen Weighs in on FDA's Pharma PR Crackdown – 'Stick to the Data'
Foley & Lardner LLP partner David Rosen shared insights on the regulatory challenges pharmaceutical companies face when publicly communicating around new cancer therapies in the MM+M article, “When a podcast becomes promotion: Inside the FDA’s warning shot at ImmunityBio.”
April 2, 2026
In the News
Susan Poll Klaessy and Adrienne Walker Named Chair and Vice Chair of Foley’s Bankruptcy & Business Reorganizations Practice
Foley & Lardner LLP partner Susan Poll Klaessy was appointed chair of the firm’s global Bankruptcy & Business Reorganizations Practice Group. Partner Adrienne Walker will serve as vice chair, supporting the continued growth and strategic direction of the practice.
April 1, 2026
In the News
Foley Featured on Top 10 Sales of 2025 List by Golf Inc.
Foley & Lardner LLP advised on two transactions named among Golf Inc.’s Top 10 Sales of 2025.